CN116120408A - B cell epitope target antigen carrying helicobacter pylori virulence factor, expression vector and application thereof - Google Patents
B cell epitope target antigen carrying helicobacter pylori virulence factor, expression vector and application thereof Download PDFInfo
- Publication number
- CN116120408A CN116120408A CN202211599991.0A CN202211599991A CN116120408A CN 116120408 A CN116120408 A CN 116120408A CN 202211599991 A CN202211599991 A CN 202211599991A CN 116120408 A CN116120408 A CN 116120408A
- Authority
- CN
- China
- Prior art keywords
- agglutination
- target antigen
- tbea
- recombinant
- helicobacter pylori
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091007433 antigens Proteins 0.000 title claims abstract description 94
- 102000036639 antigens Human genes 0.000 title claims abstract description 94
- 239000000427 antigen Substances 0.000 title claims abstract description 76
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 59
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 59
- 210000003719 b-lymphocyte Anatomy 0.000 title claims abstract description 29
- 239000000304 virulence factor Substances 0.000 title claims abstract description 29
- 230000007923 virulence factor Effects 0.000 title claims abstract description 29
- 239000013604 expression vector Substances 0.000 title claims description 37
- 230000004520 agglutination Effects 0.000 claims abstract description 132
- 238000001514 detection method Methods 0.000 claims abstract description 86
- 108090000623 proteins and genes Proteins 0.000 claims description 73
- 241000894006 Bacteria Species 0.000 claims description 62
- 241000607132 Salmonella enterica subsp. enterica serovar Gallinarum Species 0.000 claims description 41
- 230000028327 secretion Effects 0.000 claims description 41
- 239000013598 vector Substances 0.000 claims description 31
- 238000003259 recombinant expression Methods 0.000 claims description 27
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 238000010276 construction Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 102000003712 Complement factor B Human genes 0.000 claims description 2
- 108090000056 Complement factor B Proteins 0.000 claims description 2
- 238000012360 testing method Methods 0.000 abstract description 27
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 abstract description 24
- 230000035945 sensitivity Effects 0.000 abstract description 20
- 101100476480 Mus musculus S100a8 gene Proteins 0.000 abstract description 14
- 238000005516 engineering process Methods 0.000 abstract description 7
- 230000000405 serological effect Effects 0.000 abstract description 6
- 229920000642 polymer Polymers 0.000 abstract description 3
- 241001052560 Thallis Species 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 118
- 239000013612 plasmid Substances 0.000 description 43
- 230000001580 bacterial effect Effects 0.000 description 39
- 239000013642 negative control Substances 0.000 description 38
- 239000000725 suspension Substances 0.000 description 38
- 241000588724 Escherichia coli Species 0.000 description 35
- 239000000047 product Substances 0.000 description 33
- 108020004414 DNA Proteins 0.000 description 30
- 238000012408 PCR amplification Methods 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 101150002564 Brsk2 gene Proteins 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 17
- 238000001962 electrophoresis Methods 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 238000012795 verification Methods 0.000 description 16
- 230000003321 amplification Effects 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 238000003199 nucleic acid amplification method Methods 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 12
- 229960000723 ampicillin Drugs 0.000 description 12
- 230000001717 pathogenic effect Effects 0.000 description 12
- 241000287828 Gallus gallus Species 0.000 description 11
- 235000013330 chicken meat Nutrition 0.000 description 11
- 241000271566 Aves Species 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 241000607142 Salmonella Species 0.000 description 9
- 238000001976 enzyme digestion Methods 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 239000011543 agarose gel Substances 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 8
- 229960005542 ethidium bromide Drugs 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 101150092364 sadA gene Proteins 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 206010019375 Helicobacter infections Diseases 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 5
- 230000004523 agglutinating effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 241000589875 Campylobacter jejuni Species 0.000 description 4
- 102000012410 DNA Ligases Human genes 0.000 description 4
- 108010061982 DNA Ligases Proteins 0.000 description 4
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000008029 eradication Effects 0.000 description 4
- 238000012113 quantitative test Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 241000272525 Anas platyrhynchos Species 0.000 description 3
- 241000589989 Helicobacter Species 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000009589 serological test Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010051226 Campylobacter infection Diseases 0.000 description 2
- 241001137307 Cyprinodon variegatus Species 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 229940124857 Salmonella typhi vaccine Drugs 0.000 description 2
- 108010073429 Type V Secretion Systems Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- -1 polar amino acid Chemical class 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 238000012257 pre-denaturation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012134 rapid urease test Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000012355 Integrin beta1 Human genes 0.000 description 1
- 108010022222 Integrin beta1 Proteins 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 206010058780 Meningitis neonatal Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010046504 Type IV Secretion Systems Proteins 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 101150114014 cagA gene Proteins 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000007896 negative regulation of T cell activation Effects 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000009893 qingqiao Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56922—Campylobacter
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/42—Salmonella
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a B cell epitope target antigen (TBEA) carrying helicobacter pylori Hp virulence factors CagA and VacA and application thereof in the expression and detection of Hp agglutination antibodies of Salmonella typhi SadA type and YaiU type T5SS, respectively. The specific TBEA of the invention is derived from CagA and VacA respectively, and is expressed by using two types of T5SS respectively. Through an indirect agglutination test, the surface energy of the thalli is verified to be two TBEAs, the two TBEAs accurately identify and combine with antibodies aiming at Hp to form a TBEA-antibody complex polymer, and the TBEA-antibody complex polymer is clearly visible to naked eyes, so that specific, sensitive and rapid Hp agglutination antibody detection is realized. The invention can specifically detect the specific agglutination antibody, the sensitivity is obviously higher than that of the traditional serological detection technology based on protein antigen, and the titer of the specific agglutination antibody can be quantitatively detected.
Description
Technical Field
The invention belongs to the technical field of biomedicine and immunodiagnosis detection, and particularly relates to a B cell epitope target antigen carrying helicobacter pylori virulence factors, an expression vector and application thereof, which are divisional applications with application date 2022, 12 and 9 and application number 202211587776.9.
Background
Helicobacter pylori (Helicobacter pylori, hpylori, hp) is a microaerophilic gram-negative bacterium, and is a main causative agent of various gastrointestinal diseases in humans, and can survive in a very low pH environment in the stomach through a urease utilization system, targeting parietal cells, gastric acid and other mechanisms, and is infected through a digestive meatus-mouth, faecal-mouth and other transmission routes, and it has been reported that more than 50% of people worldwide are infected, and chronic gastritis, peptic ulcer, mucosa-associated lymphoid tissue lymphoma, and even gastric cancer can be caused. Since most of patients in clinic are in an asymptomatic bacteria-carrying state and are not paid attention to the situation, so that serious diseases such as illness development and gastric cancer can be possibly caused, helicobacter pylori is listed as a class I cancerogenic substance at present, and eradication of the helicobacter pylori is also listed as a main strategy for preventing gastric cancer. In addition, in view of the lack of effective prevention and control of vaccine for helicobacter pylori infection at present and the increasingly serious problem of multi-drug resistance of the helicobacter pylori, the eradication effect of the helicobacter pylori is poor in clinic. Therefore, accurate detection techniques are critical for preventing infection by helicobacter pylori and for assessing whether intervention therapy eradicates the bacteria, and are also important means for assessing the efficacy of treatment after infection.
The method for detecting helicobacter pylori mainly comprises a urea expiration test, a rapid urease test, fecal antigen detection, serological examination, endoscopy, histopathological examination, polymerase chain reaction and bacterial culture, and has certain limitation in clinic, such as uncertainty of a set critical value (usually a threshold average value of a certain population number) in result judgment in the methods of the urea expiration test, the rapid urease test, the fecal antigen detection, the interference influence of using drugs, the operation difference of technicians and the like, and the sample source limitation and sampling of the polymerase chain reaction and bacterial culture are not easy. Currently, there is no unification of the "gold standard" for helicobacter pylori detection. In recent years, more and more medical guidelines suggest the use of urea breath tests as the primary non-invasive means of diagnosing helicobacter pylori, but the average value of the threshold values set in the outcome determination does have uncertainty for a particular individual, and studies indicate that the threshold values affect the specificity of the test over a population of individuals, while there is no criterion how clearly to select the appropriate threshold values, which in fact are inconsistent for each individual. Serological tests based on various protein antigens of helicobacter pylori are currently generally considered not to be suitable for early diagnosis of helicobacter pylori infection, nor are they used as a technical means for assessing whether eradication therapy is successful, because in classical serological tests based on protein antigens specific antibodies will only appear in blood after several weeks of infection with helicobacter pylori, false negative results will appear if antibodies produced at an early stage do not reach the detection threshold for some individuals, while antibodies in serum after eradication of helicobacter pylori, whose protein antigen detection antibody titer can be maintained for more than 6 months, are prone to false positives, and serological tests based on protein antigens are generally not used for the screening after interventional therapy. Although PCR detection has high sensitivity, bacterial culture is generally regarded as a "gold standard" for detecting helicobacter pylori infection, the sensitivity of the method is low, considering that PCR detection and bacterial culture are limited in sample source and difficult to sample, and are susceptible to sample quality, transportation conditions and time, environment and technician operation differences.
Thus, a specific sensitive, rapid, convenient and inexpensive method for early accurate diagnosis, monitoring and vaccination efficacy assessment of h.pyri infection is to be developed.
Disclosure of Invention
The invention aims to: the technical problem to be solved by the invention is to provide B cell epitope target antigens based on carrying helicobacter pylori virulence factors, wherein the virulence factors comprise CagA and VacA. The invention can perform early accurate diagnosis of H.pyri infection and vaccination efficacy assessment with specificity sensitivity, rapidness, convenience and low cost.
The technical problem to be solved by the present invention is to provide a nucleic acid or gene encoding said target antigen.
The invention also solves the technical problem of providing an expression cassette, a recombinant expression vector, a recombinant strain and an agglutination antibody detection system.
The invention also solves the technical problem of providing a recombinant expression vector, an agglutination antibody detection system or a construction method of a recombinant strain.
The invention also solves the technical problem of providing a target antigen, nucleic acid or gene encoding the target antigen, an expression cassette, a recombinant vector, a recombinant strain or an agglutination antibody detection system and application thereof in preparing a reagent or a kit for detecting helicobacter pylori antibodies.
The invention also solves the technical problem of providing an agglutination antibody which binds to a B cell epitope target antigen of helicobacter pylori virulence factor CagA.
The invention finally solves the technical problem of providing a reagent or a kit for detecting helicobacter pylori agglutination antibodies.
The technical scheme is as follows: in order to solve the technical problems, in one aspect, the invention provides a B cell epitope target antigen carrying helicobacter pylori virulence factor CagA, wherein the amino acid sequence of the target antigen is GDNGGPEARHD, and the target antigen is named Hp-CagA-TBEA-GD11.
The invention also includes a nucleic acid or gene encoding the target antigen, the DNA sequence of which is GGGGATAATGGTGGTCCTGAAGCTAGGCATGAT.
The invention also comprises an expression cassette, a recombinant expression vector and a recombinant strain, and the recombinant strain comprises the nucleic acid or the gene.
Preferably, the recombinant expression vector is pBR-SadA-Hp-CagA-TBEA.
The invention also includes an agglutination antibody detection system comprising said expression cassette, recombinant expression vector or recombinant strain.
The recombinant expression vector is obtained by inserting nucleic acid or gene of the target antigen into a gene sequence of a V-shaped secretion system (Type V secretion system, T5 SS) of Salmonella typhi SadA type.
Wherein the recombinant strain is obtained by introducing a recombinant expression vector into a vector bacterium.
The invention also discloses a recombinant expression vector, an agglutination antibody detection system or a construction method of the recombinant strain, which comprises the following steps:
(1) Obtaining a B cell epitope target antigen DNA sequence carrying helicobacter pylori virulence factor CagA; the DNA sequence is GGGGATAATGGTGGTCCTGAAGCTAGGCATGAT;
(2) Inserting the DNA sequence obtained in the step (1) into a gene sequence of a V-type secretion system of salmonella gallinarum SadA type to construct a recombinant expression vector; or/and;
(3) And (3) introducing the recombinant expression vector obtained in the step (2) into a vector bacterium in an electrotransformation mode to obtain the recombinant strain.
Preferably, the expression vector pBR-SadA-Hp-CagA-TBEA is introduced into a vector bacterium in an electrotransformation mode, and the indirect agglutination test is used for verifying that the vector bacterium expresses a V-type secretion system of salmonella gallinarum SadA type, and the surface of the bacterium can successfully display the expression of Hp-CagA-TBEA.
The invention also comprises a target antigen, nucleic acid or gene for encoding the target antigen, and application of the expression cassette, recombinant vector, recombinant strain or agglutination antibody detection system in preparation of a reagent or kit for detecting helicobacter pylori antibodies.
The present invention also includes agglutination antibodies that bind to B cell epitope target antigens of H.pylori virulence factor CagA, said agglutination antibodies specifically binding to said B cell epitope target antigens.
The invention also comprises a reagent or a kit for detecting helicobacter pylori agglutination antibodies, wherein the reagent or the kit comprises the B cell epitope target antigen, the expression cassette, a recombinant vector, a recombinant strain or the agglutination antibody detection system.
In the present invention, the whole genome of helicobacter pylori encodes various virulence factors, and the cagA gene encoded protein is used as the main virulence factor of helicobacter pylori to determine the pathogenicity. Highly pathogenic H.pylori strains contain an approximately 40kb pathogenic island (cag PAI) carrying more than 30 genes encoding a functional type IV secretion system (Type IVsecretion system, T4 SS). T4SS is a syringe-like delivery device consisting of a pilus-like structure and extracellular portion of the transmembrane, delivering CagA to the host target cell. CagA is a major effector protein that binds to the host cell receptor integrin β1 into epithelial cells, interacts with a variety of proteins and disrupts the normal signal transduction pathways of the cell, such as the mitogen activated protein kinase family (MAPK) pathway, and causes a series of dysfunctions in the epithelial cells leading to cytopathy.
VacA, which is also the major causative factor in the initiation of infection as an H.pyri virulence factor, encodes a 140kDa protein precursor and cleaves the N-and C-termini by an autotransporter mechanism to produce an 88kDa mature secreted toxin, vacuolated cytotoxin (VacA). The 88kDa mature toxin molecule is transported through the outer membrane and can then be released extracellular as a soluble protein or on the bacterial surface, after which it is cleaved into two domains: p33, p55 play an important role in mediating VacA binding to host cells. VacA molecules have a variety of functions, such as cavitation of host cells, targeted mitochondrial induction of apoptosis, inhibition of T-cell activation proliferation, etc., and thus colonize gastric epithelial cells.
Thus, in another aspect, the invention also provides a B cell epitope target antigen carrying helicobacter pylori virulence factor VacA, the amino acid sequence of the target antigen is ANVEARYYYGD, and the target antigen is named Hp-VacA-TBEA-AD11.
The invention also includes a nucleic acid or gene encoding the target antigen, the DNA sequence of the nucleic acid or gene being GCTAATGTGGAAGCGCGCTATTATTATGGAGAC.
The invention also comprises an expression cassette, a recombinant expression vector and a recombinant strain, and the recombinant strain comprises the nucleic acid or the gene.
The invention also includes an agglutination antibody detection system comprising said expression cassette, recombinant expression vector or recombinant strain.
The recombinant expression vector is obtained by inserting nucleic acid or gene of the target antigen into a gene sequence of a V-type secretion system of salmonella gallinarum YaiU type.
Preferably, the recombinant expression vector is pBR-YaiU-Hp-VacA-TBEA.
Wherein the recombinant strain is obtained by introducing a recombinant expression vector into a vector bacterium.
The recombinant expression vector, the agglutination antibody detection system or the construction method of the recombinant strain provided by the invention comprises the following steps:
(1) Obtaining a B cell epitope target antigen DNA sequence carrying helicobacter pylori virulence factor VacA; the DNA sequence is GCTAATGTGGAAGCGCGCTATTATTATGGAGAC;
(2) Inserting the DNA sequence obtained in the step (1) into a gene sequence of a V-type secretion system of salmonella gallinarum YaiU type to construct a recombinant expression vector; or/and;
(3) And (3) introducing the recombinant expression vector obtained in the step (2) into a vector bacterium in an electrotransformation mode to obtain the recombinant strain.
Preferably, the recombinant expression vector pBR-YaiU-Hp-VacA-TBEA is introduced into a vector bacterium, and the vector bacterium is verified to express a V-type secretion system of salmonella gallinarum YaiU type through an indirect agglutination test, and the surface of the bacterium can successfully display the expression Hp-VacA-TBEA.
The invention also comprises the application of the helicobacter pylori virulence factor B cell epitope target antigen, the nucleic acid or gene for encoding the target antigen, the expression cassette, the recombinant vector, the recombinant strain or the agglutination antibody detection system in the preparation of a reagent or a kit for detecting helicobacter pylori antibodies.
The present invention also includes agglutination antibodies that bind to B cell epitope target antigens of H.pylori virulence factor VacA, said agglutination antibodies specifically binding to said B cell epitope target antigens.
The invention also comprises a reagent or a kit for detecting helicobacter pylori agglutination antibodies, wherein the reagent or the kit comprises the B cell epitope target antigen, the expression cassette, a recombinant vector, a recombinant strain or the agglutination antibody detection system.
The beneficial effects are that: compared with the prior art, the invention has the following remarkable advantages:
1. according to the invention, the SadA type V-shaped secretion system is used for displaying and expressing target antigens instead of complete protein antigens, and the quantity of the target antigens is amplified by expressing on the surface of carrier bacteria, so that the specificity and sensitivity of antibody detection are greatly improved; meanwhile, the target antigen (CagA-TBEA) is used for replacing the complete protein antigen (CagA-protein), and in fact, the CagA-TBEA is the epitope which is combined with and recognizes the specific agglutination antibody, and the specific recognition reaction of the target antigen antibody removes various background reactions caused by the existence of non-target antigens in the protein antigen, so that the specific specificity of the detection method is effectively ensured. The V-type secretion system based on the SadA type shows the expression target antigen, the indirect agglutination test verifies that the carrier bacteria express the V-type secretion system of the Salmonella typhi SadA type, the surface of the bacteria successfully shows the expression Hp-CagA-TBEA, the preparation of protein antigens required by the traditional serological detection method is not needed, the steps of heterologous expression, purification, coating, non-specific cleaning and the like of the protein antigens are not needed, and meanwhile, various background reactions caused by the existence of the non-target antigens in the protein antigens are removed, so that the specific recognition and the specific binding of the antigen epitope to the specific agglutination antibody are ensured, and the specific sensitivity is ensured.
2. The invention explores the B cell epitope target antigen (TBEA) of virulence factor VacA based on the role of VacA protein molecules in starting H.pyri infection and pathogenicity, and the invention displays the expression target antigen through a V-type secretion system of YaiU type, and displays the expression amplified target antigen quantity on the surface of carrier bacteria, thereby greatly improving the sensitivity of antibody detection; meanwhile, the target antigen is utilized to replace the complete protein antigen, in fact, the VacA target antigen is the antigen epitope of the specific agglutination antibody, the specific specificity of the detection method is effectively ensured by the target antigen antibody reaction, and the technical bottleneck limitation of various background reactions caused by the existence of non-target antigens in the protein antigen antibody reaction is overcome. The invention is based on the V-type secretion system of YaiU type, and the indirect agglutination test verifies that the vector bacteria express the V-type secretion system of Salmonella typhi YaiU type, the surface of the bacteria successfully displays and expresses Hp-VacA-TBEA, a TBEA-antibody complex polymer can be formed, the naked eyes can clearly see the preparation of protein antigens required by the traditional serological detection method, the steps of heterologous expression, purification, coating, non-specific cleaning and the like of the protein antigens are not needed, and the specific recognition and the specific binding of specific agglutination antibodies of antigen epitopes can be ensured.
Drawings
FIG. 1, schematic structural diagram of V-type secretion system of Salmonella typhi SadA type.
FIG. 2, PCR amplification identification electrophoretogram of the gene encoding the Salmonella typhi SadA type V-type secretion system (sadA gene). Wherein lane M is Trans 2K plus II DNA Marker, lane 1 is PCR amplification product of Salmonella typhi standard strain NCTC 13346; lane 2 is the PCR amplification product of salmonella gallinarum vaccine strain SG 01; lane 3 is the PCR amplification product of Salmonella gallinarum isolate C79-23; lane 4 is the genome of the avian pathogenic escherichia coli isolate APEC-XM as a negative control; lane 5 is the genome of the engineered escherichia coli dh5α as a negative control.
FIG. 3, an electrophoresis chart of nucleic acids identified by cleavage of the expression vector pBR-SadA. Wherein lane M is Trans 2K plus II DNA Marker, lane 1 is a recombinant circular plasmid pBR-SadA, lane 2 is a BamHI single cut pBR-SadA DNA band, lane 3 is a SalI single cut pBR-SadA DNA band, and lane 4 is a BamHI and SalI double cut pBR-SadA DNA band.
FIG. 4 PCR amplification identification electrophoretogram of sadA-Hp-CagA-TBEA-GD11 after insertion of Hp-CagA-TBEA-GD11 sequence. Wherein, lane M is Trans 2K Plus II DNA Marker, lane 1 is PCR amplified product of sadA gene, and the template DNA is derived from Salmonella gallinarum standard strain NCTC13346 as positive control; lane 2 is the PCR amplification product of sadA-Hp-CagA-TBEA-GD 11; lane 3 is the genome of the avian pathogenic escherichia coli isolate APEC-XM as a negative control; lane 5 is the genome of the engineered escherichia coli dh5α as a negative control.
FIG. 5, an electrophoretogram of the recombinant plasmid pBR-SadA-Hp-CagA-TBEA-GD11 containing the sadA-Hp-CagA-TBEA-GD11 gene. Wherein lane M is Trans2K PlusII DNA Marker, lane 1 is pBR322 circular plasmid negative control; lane 2 is the pBR-SadA-Hp-CagA-TBEA-GD11 circular plasmid; lane 3 is the BamHI single cut product of pBR-SadA-Hp-CagA-TBEA-GD 11; lane 4 is the SalI single cleavage product of pBR-SadA-Hp-CagA-TBEA-GD 11; lane 5 is the BamHI and SalI double digested product of pBR-SadA-Hp-CagA-TBEA-GD 11.
FIG. 6, schematic representation of the expression vector pBR-SadA-Hp-CagA-TBEA-GD11 recombinant plasmid.
FIG. 7 shows the results of agglutination reactions of carrier bacteria DH-5α+SadA-Hp-CagA-TBEA-GD11 with H.pyri positive sera from different sources, respectively. A: negative individual control 1, non-agglutination of Hp agglutination antibody detection system with serum samples of healthy human volunteers (uninfected with helicobacter pylori); b: negative individual control 2, hp agglutination antibody detection system and healthy SPF mouse serum sample are not agglutinated; c: agglutination of Hp agglutination antibody detection system with serum sample of mice artificially infected with helicobacter pylori; d: the Hp agglutination antibody detection system diagnoses the agglutination reaction of the serum sample of the volunteer of the patient with helicobacter pylori infection; e: the negative control 1, hp agglutination antibody detection system and the positive serum sample of the mouse helicobacter hepaticum are not agglutinated; f: negative control 2, hp agglutination antibody detection system and mouse-derived positive serum sample of human campylobacter jejuni are not agglutinated; g: negative control 3, hp agglutination antibody detection system and O2 colibacillus positive serum sample are not agglutinated; h: negative control 4, hp agglutination antibody detection system and O78 colibacillus positive serum sample are not agglutinated; i: negative control 5, hp agglutination antibody detection system and O157 E.coli positive serum sample are not agglutinated; j: negative control 6, hp agglutination antibody detection system and duck salmonella positive serum sample are not agglutinated; k: negative control 7, hp agglutination antibody detection system and Salmonella typhimurium positive serum sample did not agglutinate.
FIG. 8 shows the results of quantitative test of antibody titer of Hp-CagA agglutination antibody detection system.
FIG. 9, schematic structural diagram of V-type secretion system of Salmonella typhi YaiU type.
FIG. 10, PCR amplification identification electrophoretogram of the YaiU encoding gene (yaiU gene) of Salmonella typhi V-type secretion system of chicken. Wherein lane M is Trans 2K plus II DNA Marker, lane 1 is PCR amplification product of Salmonella typhi standard strain NCTC 13346; lane 2 is the PCR amplification product of salmonella gallinarum vaccine strain SG 01; lane 3 is the genome of the avian pathogenic escherichia coli isolate APEC-XM as a negative control; lane 4 is the genome of the engineered escherichia coli dh5α as a negative control.
FIG. 11 shows an electrophoresis pattern of nucleic acids identified by cleavage of the expression vector pBR-YaiU. Wherein lane M is Trans 2K plus II DNA Marker, lane 1 is recombinant circular plasmid pBR-YaiU, lane 2 is BamHI single cut pBR-YaiU DNA band, lane 3 is SalI single cut pBR-YaiU DNA band, and lane 4 is BamHI and SalI double cut pBR-YaiU DNA band.
FIG. 12 PCR amplification identification electrophoretogram of yaiU-Hp-VacA-TBEA-AD11 after insertion of Hp-VacA-TBEA-AD11 sequence. Wherein lane M is Trans 2K Plus II DNA Marker, lane 1 is PCR amplified product of yaiU gene, and the template DNA is derived from Salmonella gallinarum standard strain NCTC 13346 as positive control; lane 2 is the PCR amplification product of yaiU-Hp-VacA-TBEA-AD 11; lane 3 is the genome of the avian pathogenic escherichia coli isolate APEC-XM as a negative control; lane 5 is the genome of the engineered escherichia coli dh5α as a negative control.
FIG. 13, restriction enzyme identification electrophoresis diagram of recombinant plasmid pBR-YaiU-Hp-VacA-TBEA-AD11 containing yaiU-Hp-VacA-TBEA-AD11 gene. Wherein lane M is Trans 2K Plus II DNA Marker, lane 1 is pBR322 circular plasmid negative control; lane 2 is the pBR-YaiU-Hp-VacA-TBEA-AD11 circular plasmid; lane 3 is the BamHI single cut from pBR-YaiU-Hp-VacA-TBEA-AD 11; lane 4 is the SalI single cleavage product of pBR-YaiU-Hp-VacA-TBEA-AD 11; lane 5 is the BamHI and SalI double digested product of pBR-YaiU-Hp-VacA-TBEA-AD 11.
FIG. 14, schematic representation of the expression vector pBR-YaiU-Hp-VacA-TBEA-AD 11.
FIG. 15 shows the results of agglutination reactions of H.pyri-agglutination antibody detection system DH-5a+YaiU-Hp-VacA-TBEA-AD11 with H.pyri-positive serum from different sources. A: negative individual control 1, hp agglutination antibody detection system was non-agglutinating with healthy human volunteer (non-helicobacter pylori infected) serum samples; b: negative individual control 2, hp agglutination antibody detection system and healthy SPF mouse serum sample are not agglutinated; c: agglutination of Hp agglutination antibody detection system with serum sample of mice artificially infected with helicobacter pylori; d: the Hp agglutination antibody detection system diagnoses the agglutination reaction of the serum sample of the volunteer of the patient with helicobacter pylori infection; e: the negative control 1, hp agglutination antibody detection system and the positive serum sample of the mouse helicobacter hepaticum are not agglutinated; f: negative control 2, hp agglutination antibody detection system and mouse-derived positive serum sample of human campylobacter jejuni are not agglutinated; g: negative control 3, hp agglutination antibody detection system and O2 colibacillus positive serum sample are not agglutinated; h: negative control 4, hp agglutination antibody detection system and O78 colibacillus positive serum sample are not agglutinated; i: negative control 5, hp agglutination antibody detection system and O157 E.coli positive serum sample are not agglutinated; j: negative control 6, hp agglutination antibody detection system and duck salmonella positive serum sample are not agglutinated; k: negative control 7, hp agglutination antibody detection system and Salmonella typhimurium positive serum sample did not agglutinate.
FIG. 16 shows the results of quantitative test of antibody titer of Hp-VacA agglutination antibody detection system.
Detailed Description
Before further describing the embodiments of the present invention, it should be understood that: the scope of the invention is not limited to the specific embodiments described below; it should also be appreciated that: the terminology used in the examples of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the scope of the invention. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition to the specific methods, devices, materials used in the embodiments, any methods, devices, and materials of the prior art similar or equivalent to those described in the embodiments of the present invention may be used to practice the present invention according to the knowledge of one skilled in the art and the description of the present invention.
Example 1 cloning of Salmonella typhi SadA-type V-type secretion System Gene and demonstration of function at the surface of vector bacteria SadA
The salmonella SadA-type V-type secretion system, a key virulence factor located on the bacterial surface, consists of an N-terminal signal peptide sequence, a passenger domain, a linker and a β -domain 4 moiety (fig. 1). Wherein, the passenger carrying domain can display a special functional peptide segment to the outside of cells in the secretion process, and the helicobacter pylori specific TBEA of the invention is expressed through the surface display of a SadA type V-shaped secretion system. Thus, cloning and functional identification of a SadA-type V-type secretion system gene are a prerequisite for the present invention. Based on amplification and identification of a Salmonella gallinarum source SadA type V-type secretion system gene, cloning the gene into a pBR322 expression plasmid, introducing the recombinant plasmid pBR-SadA into an escherichia coli carrier strain for amplification expression in an electrotransformation mode, and further, indirectly agglutinating the recombinant engineering bacteria suspension carrying the recombinant plasmid pBR-SadA with salmonella gallinarum positive serum to show obvious agglutination, so as to verify the escherichia coli carrier strain to functionally express the Salmonella gallinarum SadA type V-type secretion system. The specific implementation procedure is as follows:
Molecular cloning primers were designed based on NCBI published Salmonella gallinarum (Salmonella Gallinarum) NCTC 13346 whole genome sequence, the upstream primer SP sadA Up 5' -GACGGATCCATGAATAGAATATTTAAAGTCCTCTGGAAT-3', downstream primer SP sadA Down 5' -CGCGTCGACTTACCACTGGAAGCCCG-3', the underlined sequences represent BamHI and SalI restriction sites, respectively, and the primers were synthesized by Nanjing qing Biotechnology Inc.
The genome of the salmonella gallinarum NCTC 13346 strain is used as a template, and the upstream primer SP sadA Up/Down is used for PCR amplification, wherein the amplification system is as follows: 2X Phanta Max Buffer. Mu.L, dNTPs 1. Mu.L, 2. Mu.L each of the upstream and downstream primers (10 mM), 1. Mu.L of NCTC 13346 genome (250 ng/. Mu.L) and 18. Mu.L of ultrapure water. The above systems were mixed uniformly and then subjected to PCR amplification by a thermal cycler (Bio-Red) as follows: the pre-denaturation is carried out at 95 ℃ for 3min, the amplification stage comprises 35 cycles of denaturation at 95 ℃ for 30s, annealing at 56.5 ℃ for 30s and extension at 72 ℃ for 4.5min, further amplification is carried out at 72 ℃ for 5min, and the temperature is reduced to 12 ℃ after the amplification is finished. The genomes of Salmonella gallinarum vaccine strains SG01 (Dai, peng; wu, hu-Cong; ding, hai-Chuan; li, shou-Jun; bao, en-Dong; yang, bao-Shou; li, ya-Jie; gao, xiao-Lei; duan, qiang-de; zhu, guo-Qiang.safety and protective effects of an avirulent Salmonella Gallinarum isolate as a vaccine candidate against Salmonella Gallinarum infections in young chickens [ J ]. Veterinary Immunology and Immunopathology,2022.253:110501 ]) and Salmonella gallinarum standard strain C79-23 (purchased from China veterinary drug administration center); the genomes of avian pathogenic E.coli isolate APEC-XM (Liu Guji, wu Hu, yin Yi, zhang Dong, xia, ren Wenkai, zhu Guojiang. Construction studies of model of E.coli-induced neonatal meningitis mice [ J ]. Chinese poultry, 2019, 41 (10): 26-30.) and E.coli engineering strain DH 5. Alpha. Were used as negative controls.
Preparing 1% agarose gel, carrying out electrophoresis for 45min at 110V, then dyeing by using ethidium bromide, and carrying out imaging observation under an ultraviolet imager, wherein the result is shown in a graph in FIG. 2, and the DNA products of 4276bp are amplified from a salmonella gallinarum standard strain NCTC13346, a salmonella gallinarum vaccine strain SG01 and a salmonella gallinarum isolate strain C79-23; no bands were amplified in the genomes of the avian pathogenic E.coli isolate APEC-XM and E.coli engineering strain DH 5. Alpha. PCR amplification product of Salmonella typhi standard strain NCTC13346 genome was extracted using a universal DNA purification kit (Tiangen Biochemical technology (Beijing) Co., ltd.).
The pBR322 plasmid (commercial plasmid, available from vast Proc. No. P0090) was extracted, the sadA gene of SalI and SalI restriction enzymes (NEB) of Salmonella typhi chicken Standard strain NCTC13346 (Genbank accession No. AM933173.1, 3931983-3936183) was digested separately with the pBR322 plasmid, and the above-mentioned linear DNA fragments were then ligated overnight in a 16℃metal bath using T4DNA ligase (NEB), and the ligation product was transformed into DH-5a competent cells the following day (red star, zhang Qingqiao, fan Baoliang. A simple and efficient E.coli competent cell preparation method [ J ]. Anhui agricultural sciences, 2008 (29): 12627-12628.) by plating with ampicillin solid medium containing 100. Mu.g/mL. Single colonies on the plates are picked and inoculated into LB liquid medium containing 100 mug/mL ampicillin to grow to a plateau, and plasmids are extracted and subjected to NheI and SalI single enzyme digestion and two restriction enzymes. 1% agarose gel is prepared, after electrophoresis for 45min at 110V, ethidium bromide is used for staining, and then imaging observation is carried out under an ultraviolet imager, the result is shown in FIG. 3, the BamHI and SalI single digestion products of the recombinant plasmid pBR-SadA are 8363bp, the double digestion products are a 4085bp linear vector and a 4278bp SadA linear DNA fragment, the sizes of the fragments are consistent with the expected sizes, and the DNA sequencing verification is carried out (Nanjing qing department biotechnology Co., ltd.).
Recombinant plasmid pBR-SadA DH-5a engineering bacteria carrying sadA gene are grown in ampicillin LB liquid medium containing 100 mug/mL for 14 hours to a plateau period, centrifugated at 4000rpm for 5 minutes, and the supernatant is discarded, resuspended in an equal volume of sterile physiological saline, and centrifugally washed for 2 times to prepare bacterial suspension (final concentration 1 multiplied by 10) 10 CFU/mL). The recombinant DH-5a engineering bacteria suspension is subjected to an agglutination test with SPF chicken negative serum (Beijing Bolin Yinggahn company) and chicken salmonella typhi positive serum (obtained by immunizing SPF chicken twice by chicken salmonella typhi vaccine strain SG01 and collecting blood 45 days after immunization) and then separating out, and bacterial suspension of DH-5a engineering bacteria containing pBR322 empty vector is used as a negative control. The results are shown in Table 1, where bacterial suspensions of both strains did not react with negative serum. The DH-5 alpha engineering bacteria suspension carrying the recombinant plasmid pBR-SadA and positive serum have obvious agglutination phenomenon, large agglutination particles and clear background; the DH-5 alpha engineering bacteria suspension containing the pBR322 empty vector and positive serum do not have agglutination phenomenon, and the background is turbid. The result shows that the SadA type V-shaped secretion system from salmonella gallinarum can be expressed on the surface of DH-5 alpha engineering bacteria in a functional way.
TABLE 1 functional verification of DH-5 alpha engineering bacteria expressing Salmonella gallinarum SadA carrying recombinant plasmid pBR-SadA
EXAMPLE 2 construction of SadA-type V-type secretion System expression vector carrying B cell epitope target antigen (TBEA) of H.pylori virulence factor CagA and verification of functional expression thereof
Based on cloning of Salmonella typhi V-type secretion system SadA gene and function verification on the surface display of carrier bacteria, a B cell epitope TBEA DNA sequence of helicobacter pylori (H.pyri) virulence factor CagA is inserted into the Salmonella typhi V-type secretion system gene sequence, an expression carrier pBR-SadA-Hp-TBEA is constructed, the expression carrier pBR-SadA-Hp-TBEA is introduced into colibacillus carrier bacteria for amplification expression, and the successful display of the expression pBR-SadA-Hp-TBEA on the surface of the carrier bacteria is verified. The specific implementation procedure is as follows:
h.pyrri J99 strain (Han Xiurui. Helicobacter pylori adhesin BabA protein binding domain characteristics and analysis of its effect [ D ]. Chinese disease prevention control center, 2021.) (accession number: AE 001439.1) was searched for by NCBI database (https:// www.ncbi.nlm.nih.gov /) and virulence factor CagA protein sequence (accession number: AAD 06073.1) was found from the whole genome. The resolved CagA crystal structure was found using the protein database (https:// www.rcsb.org /), thus guaranteeing the uniqueness of the TBEA of H.pylylori in the spatial structure (protein database ID referring to the crystal structure: 4 DVY). The amino acid sequence of CagA is subjected to hydrophobicity analysis by using NovoPro on-line tool (https:// www.novopro.cn/tools /), hydrophilic group is screened, further analysis and comparison are carried out on the space structure by protein analysis software Pymol (https:// Pymol. Org/2 /), and the amino acid sequence of the target antigen with better surface exposure is screened as TBEA, which is respectively: hp-CagA-TBEA-GD11: GDNGGPEARHD. The corresponding gene sequences of TBEA are respectively as follows: hp-CagA-TBEA-GD11: GGGGATAATGGTGGTCCTGAAGCTAGGCATGAT.
In the same way as above, motifs with good exposibility in the protein structure of the V-type secretion system of Salmonella typhi type were analyzed by the Pymol software as TBEA replacement regions. As shown in table 2, 8 substitution sites with good exposure were selected in the SadA protein screen, and the substitution sites were scored according to the hydrophilicity of the 8 substitution sequences because the TBEA screened above was all hydrophilic, and the scoring rule was as follows: every hydrophobic amino acid in the sequence is 1 score, every hydrophilic amino acid (including polar amino acid, acidic amino acid and basic amino acid) +1 score exists, the highest score sequence is taken as a motif for replacing TBEA, namely YHANSTEEDS, the sequence has a hydrophilicity score of 9, and the sequence comprises 10 hydrophilic amino acids, and the gene sequence is TACCACGCAAACTCAACGGAAGAAGATTCA.
Table 2 site of potential replacement of TBEA by the screened SadA protein
A chimeric gene is synthesized by Nanjing engine biotechnology Co., ltd, hp-CagA-TBEA-GD11 is used for replacing a replacement site in a sadA gene sequence, and the obtained chimeric gene is named sadA-Hp-CagA-TBEA-GD11. The above chimeric gene was used as a template (1. Mu.L, containing 1ng chimeric gene), the genome of Salmonella gallinarum standard strain NCTC13346 was used as a positive control, the avian pathogenic E.coli isolate APEC-XM genome and E.coli engineering strain DH 5. Alpha. Genome were used as negative controls, and PCR amplification was performed using a pair of primers SPsadAUp and SPsadADown as mentioned in example 1, and the PCR system and procedure were completely identical to those in example 1. Preparing 1% agarose gel, performing electrophoresis for 45min at 110V, then dyeing with ethidium bromide, imaging under an ultraviolet imager, and amplifying the positive control with 4278bp as shown in the PCR result in FIG. 4; the PCR product of sadA-Hp-CagA-TBEA-GD11 is: 4278bp; the negative control had no amplified bands. The sadA-Hp-CagA-TBEA-GD11PCR amplification product was extracted using a universal DNA purification kit (Tiangen Biochemical technology (Beijing)) Co.
The pBR322 plasmid was extracted, the sadA-Hp-CagA-TBEA-GD11 PCR amplification product was digested with BamHI and SalI restriction enzymes (NEB) and the pBR322 plasmid was digested with two enzymes, respectively, and the above-mentioned linear DNA fragments were ligated overnight in a 16℃metal bath using T4DNA ligase (NEB), and DH-5α competent cells were transformed the next day, and resistance screening was performed by coating ampicillin solid medium containing 100. Mu.g/mL. Single colonies on the plates were picked and inoculated into LB liquid medium containing 100. Mu.g/mL ampicillin to grow to the plateau phase, and after plasmid extraction, bamHI and SalI single enzyme digestion and two restriction enzymes double enzyme digestion were performed. Preparing 1% agarose gel, carrying out electrophoresis for 45min at 110V, then, carrying out ethidium bromide staining, and then, imaging under an ultraviolet imager, wherein the result is shown in FIG. 5, and the BamHI and SalI single cleavage products of the recombinant plasmid pBR-SadA-Hp-CagA-TBEA-GD11 are 8361bp and 8361bp respectively; the double enzyme digestion product bacteria of the two vectors comprise a 4085bp linear vector and a 4276bp sadA-Hp-CagA-TBEA-GD11 linear DNA fragment, which are consistent with the expected size.
DH-5 alpha engineering bacteria carrying recombinant plasmid pBR-SadA-Hp-CagA-TBEA-GD11 are grown to a plateau phase in ampicillin LB liquid medium containing 100 mu g/mL, the supernatant is discarded after centrifugation at 4000rpm for 5min, the bacterial suspension is prepared by resuspension with an equal volume of sterile physiological saline, and continuous centrifugation and washing for 2 times (final concentration 1X 10) 1 0 CFU/mL). Recombinant DH-5 alpha engineering bacteria bacterial suspension carrying the recombinant plasmid is respectively subjected to agglutination test with Hp-CagA negative serum (10 parts of SPF mouse serum and healthy human volunteer serum respectively) and Hp positive serum (10 parts of artificially infected mouse serum and 10 parts of volunteer serum of Hp infection diagnosis patient) and bacterial suspension containing DH-5 alpha engineering bacteria of pBR-SadA is used as negative control. The results are shown in Table 3, with bacterial suspensions of all strains not reacting with negative serum; the bacterial suspension of the recombinant DH-5 alpha engineering bacteria carrying the recombinant plasmid pBR-SadA-Hp-CagA-TBEA-GD11 has obvious agglutination phenomenon with positive serum, large agglutination particles and clear background; the DH-5 alpha engineering bacteria suspension containing the pBR-SadA plasmid and positive serum do not have agglutination phenomenon, have no agglutination particles, and have turbid background. The results indicate that B cell epitope target antigen (TBEA) from Hp-CagA is capable of achieving cell surface expression through a SadA-type V-type secretion system and is capable of specifically detecting antibodies to Hp.
In the antibody detection system, escherichia coli DH-5alpha+pBR-SadA bacterial suspension is used as a control system, the antibody detection system only increases TBEA to replace protein antigen, specifically recognizes and binds specific antibodies, and eliminates various background reactions and false positive reactions caused by the existence of non-target antigens in the protein antigen, so that accurate diagnosis of individuals is ensured; DH-5α+pBR-SadA-Hp-CagA-TBEA-GD11 bacterial suspension is used as an Hp specific antibody detection system, and the target antigen specifically recognizes the antibody against Hp-CagA.
TABLE 3 functional verification of expression of SadA-Hp-CagA-TBEA on DH-5. Alpha. Surface of vector bacterium
Note that: "-" represents negative for agglutination; "+" indicates positive agglutination
Example 3 specificity and sensitivity test of Hp-CagA agglutination antibody detection System
Based on functional verification that the surface of carrier bacteria DH-5 alpha exhibits expressed SadA-Hp-CagA-TBEA, the specificity and sensitivity of the Hp agglutination antibody detection system are further tested, and the specific implementation procedure is as follows:
according to the same manner as in example 2, a control system DH-5α+pBR-SadA bacterial suspension and a Hp agglutination antibody detection system DH-5α+pBR-SadA-Hp-CagA-TBEA-GD11 bacterial suspension were prepared. The three bacterial suspensions are respectively subjected to agglutination tests with serum from different background sources to verify the specificity of the agglutination antibody detection system, and the serum involved in detection comprises: 100 healthy human volunteers (uninfected helicobacter pylori) serum (provided by the university of Jiangsu north people hospital), 8 healthy SPF mouse serum (provided by the university of Yangzhou comparative medical center Zhu Guojiang professor problem group), 40 conclusively diagnosed patient serum (provided by the university of Yangzhou comparative medical center Zhu Guojiang professor group), 10 artificially infected helicobacter pylori mouse serum (provided by the university of Yangzhou comparative medical center Zhu Guojiang professor problem group), 1 mouse helicobacter pylori positive serum (provided by the university of Yangzhou comparative medical center Zhang Quan professor problem group), 8 human campylobacter jejuni positive serum (provided by the university of Beijing farm center Xu Fuzhou researchers), 10O 2 escherichia coli positive serum (provided by the university of Yangzhou comparative medical center Zhu Guojiang professor problem group), 10O 78 escherichia coli positive serum (provided by the university of Yangzhou comparative medical center Zhu Guojiang professor group), 10O 157 escherichia coli positive serum (provided by the university of Yangzhou comparative medical center Zhu Guojiang group), 10 salmonella positive serum (provided by the university of Yangzhou comparative medical center Zhu Guojiang professor group), and 10 salmonella positive serum (provided by the university of Yangzhou comparative medical center Zhu Guojiang professor group). As shown in Table 4, the serum of volunteer from 40 patients diagnosed with helicobacter pylori infection and the serum of mice artificially infected with helicobacter pylori did not agglutinate with the control system, but did agglutinate with the Hp-CagA antibody detection system; meanwhile, the system has no agglutination reaction with all healthy volunteer (non-infected helicobacter pylori) serum, healthy SPF mouse serum, liver helicobacter positive serum, mouse-derived human campylobacter jejuni infection positive serum, O2 escherichia coli positive serum, O78 escherichia coli positive serum, O157 escherichia coli positive serum, salmonella anatipestifer positive serum and salmonella typhimurium positive serum, and the specificity is 100 percent. The agglutination pattern of the serum samples is shown in FIG. 7.
Table 4, specificity verification of Hp-CagA target antigen directed agglutination antibody detection System
Note that: "-" represents negative for agglutination; "+" indicates positive agglutination
To clarify the test sensitivity of the present invention, 10C 57BL/6 mice were infected with the helicobacter pylori standard strain NTCT11639 (day 1), and the serum of the above mice was collected by tail vein blood sampling on the day before infection (day 0) as a negative control. All mice were collected whole blood and serum was prepared daily from day 1 to day 15 post infection using tail vein blood collection and then quantitatively tested using the Hp-CagA agglutination antibody detection system. The test mode is as follows: subjecting the 160 parts of serum to 2 n Dilution of the double ratio: 10 mu L of sterile physiological saline is added to each well of a 96-well plate, and then 10 mu L of serum is sucked and added to the first well of each column, and the mixture is mixed with the sterile physiological salineAfter thorough mixing of the water, 10. Mu.L of diluted serum was added to the next well and diluted to 2 in circulation 6 Multiple times. The serum of each dilution was subjected to an agglutination test with DH-5α+pBR-SadA and DH-5α+pBR-SadA-Hp-CagA-TBEA-GD11 bacterial suspensions, respectively, with DH-5α+pBR-SadA as negative control and the last dilution at which agglutinating particles appeared as the serum antibody titer. The positive rate results of the agglutination test are shown in table 5, and agglutination antibodies can be detected in infected mice at the earliest on day 5, the sensitivity is significantly higher than that of the traditional serological detection technology, and the positive rate of the agglutination test is gradually increased with the increase of infection duration; the quantitative test results are shown in fig. 8, and at day 14 post-immunization, it was determined that the infectious agglutination antibody titer reached 1:16.
In conclusion, the Hp-CagA target antigen-directed agglutination antibody test method has good specificity and sensitivity. Compared with the results reported by the current immunological detection methods (such as colloidal gold, immunoluminescence, ELISA and the like) aiming at Hp-CagA, the sensitivity of the technology is remarkably improved, and the titer of the specific agglutination antibody can be quantitatively detected.
TABLE 5 sensitivity verification of Hp-CagA target antigen directed agglutination antibody detection systems
Example 4 cloning of Salmonella typhi YaiU-type V-type secretion System Gene and demonstration of function on the surface of vector bacteria YaiU
YaiU is a V-type secretion system of salmonella comprising a virulence effector secreted at the bacterial surface, consisting of an N-terminal signal peptide sequence, a passenger domain, a linker and a β -domain 4 moiety (fig. 9). Wherein the passenger domain can display a special functional peptide fragment to the outside of the cell in the secretion process, and the helicobacter pylori specific VacATBEA of the invention is displayed and expressed through a V-shaped secretion system of YaiU type. Thus, cloning and functional identification of the YaiU gene of the V-type secretion system are the prerequisites of the present invention. Based on amplification and identification of a salmonella gallinarum source YaiU type V-type secretion system gene, cloning the gene into a pBR322 expression plasmid, introducing a recombinant plasmid pBR-YaiU into escherichia coli carrier bacteria for amplification expression in an electrotransformation mode, further, indirectly agglutinating the recombinant engineering bacteria suspension carrying the recombinant plasmid pBR-YaiU and salmonella gallinarum positive serum to show obvious agglutination, and verifying the escherichia coli carrier bacteria to functionally express the salmonella gallinarum YaiU type V-type secretion system. The specific implementation procedure is as follows:
Molecular cloning primers were designed based on NCBI published Salmonella gallinarum (Salmonella Gallinarum) NCTC 13346 whole genome sequence, the upstream primer SP YaiU Up 5' -GACGGATCCATGCACTCCTGGAAAAAGAAACT-3', downstream primer SP YaiU Down5' -CGCGTCGACTTACCAGGTATATTTAACACCAACGTT-3', the underlined sequences represent BamHI and SalI restriction sites, respectively, and the primers were synthesized by Nanjing qing Biotechnology Inc.
The genome of Salmonella typhi NCTC 13346 strain is used as a template, and the PCR amplification is carried out by using an upstream primer SP YaiU Up/Down, wherein the amplification system is as follows: 2X Phanta Max Buffer. Mu.L, dNTPs 1. Mu.L, 2. Mu.L each of the upstream and downstream primers (10 mM), 1. Mu.L of NCTC 13346 genome (200 ng/. Mu.L) and 18. Mu.L of ultrapure water. The above systems were mixed uniformly and then subjected to PCR amplification by a thermal cycler (Bio-Red) as follows: the pre-denaturation is carried out at 95 ℃ for 3min, the amplification stage comprises 35 cycles of denaturation at 95 ℃ for 30s, annealing at 56 ℃ for 30s and extension at 72 ℃ for 3min, further amplification is carried out at 72 ℃ for 5min, and the temperature is reduced to 12 ℃ after the amplification is finished. The genomes of the salmonella gallinarum vaccine strain SG01 and the salmonella gallinarum isolate C79-23 serve as positive controls; the genomes of the avian pathogenic escherichia coli isolate APEC-XM and the escherichia coli engineering bacterium DH5 alpha are used as negative controls.
Preparing 1% agarose gel, carrying out electrophoresis for 45min at 110V, then dyeing by using ethidium bromide, and carrying out imaging observation under an ultraviolet imager, wherein the result is shown in figure 10, and the DNA products of 3033bp are amplified by a salmonella gallinarum standard strain NCTC 13346, a salmonella gallinarum vaccine strain SG01 and a salmonella gallinarum isolate strain C79-23; no bands were amplified in the genomes of the avian pathogenic E.coli isolate APEC-XM and E.coli engineering strain DH 5. Alpha. PCR amplification product of Salmonella typhi standard strain NCTC 13346 genome was extracted using a universal DNA purification kit (Tiangen Biochemical technology (Beijing) Co., ltd.).
The pBR322 plasmid was extracted, the yaiU gene of Salmonella typhi standard strain NCTC 13346 (GenBank accession number AM933173.1, 423208-426163) was double digested with BamHI and Sa1I restriction enzymes (NEB), respectively, and the above-mentioned linear DNA fragments were ligated overnight in a 16℃metal bath using T4 DNA ligase (NEB), and DH-5. Alpha. Competent cells were transformed the following day, and resistant colony screening was performed by coating ampicillin solid medium containing 100. Mu.g/mL. Single colonies on the plates were picked and inoculated into LB liquid medium containing 100. Mu.g/mL ampicillin to grow to the plateau phase, and after plasmid extraction, bamHI and SalI single enzyme digestion and two restriction enzymes double enzyme digestion were performed. 1% agarose gel is prepared, after electrophoresis for 45min at 110V, ethidium bromide is used for staining, and then imaging observation is carried out under an ultraviolet imager, the result is shown in FIG. 11, the BamHI and SalI single digestion products of the recombinant plasmid pBR-YaiU are 7118bp, the double digestion products are a 4085bp linear vector and a 3033bp YaiU linear DNA fragment, the sizes of the fragments are consistent with the expected sizes, and the DNA sequencing verification is carried out (Nanjing qing department Biotechnology Co., ltd.).
DH-5 alpha engineering bacteria carrying YaiU gene recombinant plasmid pBR-YaiU are grown in ampicillin LB liquid medium containing 100 mug/mL for 14 hours to a plateau phase, centrifugated at 4000rpm for 5 minutes, and the supernatant is discarded, resuspended in an equal volume of sterile physiological saline, and centrifugally washed for 2 times to prepare bacterial suspension (final concentration 1 multiplied by 10) 10 CFU/mL). The recombinant DH-5 alpha engineering bacteria bacterial suspension is subjected to an agglutination test with SPF chicken negative serum (Beijing Bolin Yinggahn company) and chicken salmonella positive serum (SPF chicken is orally immunized twice by chicken salmonella typhi vaccine strain SG01 and is separated out after 45 days of blood sampling after immunization), and bacterial suspension of DH-5 alpha engineering bacteria containing pBR322 empty vector is used as negative control. The results are shown in Table 6, where bacterial suspensions of both strains did not react with negative serum. The DH-5 alpha engineering bacteria suspension carrying the recombinant plasmid pBR-YaiU and positive serum have obvious agglutination phenomenon, large agglutination particles and clear background; containing pBRThe DH-5 alpha engineering bacteria suspension of the 322 empty carrier and positive serum do not have agglutination phenomenon, have no agglutination particles, and the background is turbid. The results indicate that the YaiU-type V-shaped secretion system from salmonella gallinarum can be expressed on the surface of DH-5 alpha engineering bacteria in a functional way.
TABLE 6 functional verification of DH-5 alpha engineering bacteria carrying recombinant plasmid pBR-YaiU for expressing Salmonella gallinarum YaiU
EXAMPLE 5 construction of YaiU-type V secretion System expression vector carrying B cell epitope target antigen (TBEA) of helicobacter pylori virulence factor VacA and verification of functional expression thereof
Based on cloning of a V-type secretory system gene of salmonella typhi YaiU type and function verification on surface display of a carrier bacterial body, inserting a B cell epitope TBEA DNA sequence of helicobacter pylori (H.pyri) virulence factor VacA into the V-type secretory system gene sequence of salmonella typhi YaiU type, constructing an expression carrier pBR-YaiU-Hp-TBEA, introducing into escherichia coli carrier bacteria for amplification expression, and verifying that the expression pBR-YaiU-Hp-TBEA is successfully displayed on the surface of the carrier bacterial body. The specific implementation procedure is as follows:
the sequence of the H.pyrri J99 strain (accession number: AE 001439.1) was retrieved from the NCBI database (https:// www.ncbi.nlm.nih.gov /) and the virulence factor VacA protein sequence (accession number: AAD 05855.1) was found from the whole genome. The already resolved VacA crystal structure was found using the protein database (https:// www.rcsb.org /), thus guaranteeing the uniqueness of the TBEA of H.pyri in the spatial structure (protein database ID referring to the crystal structure: 6 ODY). The amino acid sequence of VacA is subjected to hydrophobicity analysis by using NovoPro on-line tool (https:// www.novopro.cn/tools /), hydrophilic group is screened, further analysis and comparison are carried out on the space structure by protein analysis software Pymol (https:// Pymol. Org/2 /), and the screened amino acid sequence of 1 target antigen with better surface exposure is TBEA, which is: hp-VacA-TBEA-AD11: ANVEARYYYGD. The corresponding gene sequence of TBEA is: hp-VacA-TBEA-AD11: GCTAATGTGGAAGCGCGCTATTATTATGGAGAC.
In the same way as above, the motif with good surface exposure in the protein structure of the V-type secretory system of Salmonella typhi YaiU type was analyzed as a TBEA substitution region by Pymol software. As shown in table 7, 8 substitution sites with good exposure were selected in total by YaiU protein screening, and since the TBEA screened above was all hydrophilic, the substitution sites were scored according to the hydrophilicity of the 8 substitution sequences, and the scoring rule was as follows: every hydrophobic amino acid in the sequence is 1 score, every hydrophilic amino acid (including polar amino acid, acidic amino acid and basic amino acid) +1 score exists, the highest score sequence is taken as a motif for replacing TBEA, namely DRTNDTTKSN, the sequence has a hydrophilicity score of 9, and the sequence comprises 10 hydrophilic amino acids, and the gene sequence is GATCGTACTAACGACACGACTAAGTCTAAC.
Table 7 sites of potential replacement of TBEA by YaiU protein selected
The chimeric gene was synthesized by Nanjing's biological technology Co., ltd, hp-VacA-TBEA-AD11 was used to replace the substitution site in the yaiU gene sequence, the chimeric gene was named yaiU-Hp-VacA-TBEA-AD11, the above chimeric gene was used as a template (1. Mu.L, containing 1ng chimeric gene), the Salmonella gallinarum standard strain NCTC13346 genome was used as a positive control, the avian pathogenic E.coli isolate APEC-XM genome and E.coli engineering strain DH 5. Alpha. Genome were used as negative controls, and PCR amplification was performed using the pair of primers SPYaiUUp and SPYaiUDown as mentioned in example 4, and the system and procedure of PCR were completely identical to those of example 4. Preparing 1% agarose gel, performing electrophoresis for 45min at 110V, then dyeing with ethidium bromide, imaging under an ultraviolet imager, and amplifying the positive control to 3033bp according to the PCR result as shown in FIG. 12; PCR products of yaiU-Hp-VacA-TBEA-AD11 were: 3033bp; the negative control had no amplified bands. PCR amplified products of YaiU-Hp-VacA-TBEA-AD11 and YaiU-Hp-VacA-TBEA-AD11 were extracted using a general-purpose DNA purification kit (Tiangen Biochemical Co., ltd.).
The pBR322 plasmid was extracted, the YaiU-Hp-VacA-TBEA-AD11 PCR amplification product was digested with BamHI and SalI restriction enzymes (NEB) and the pBR322 plasmid was digested with two enzymes, and then the above-mentioned linear DNA fragments were ligated overnight in a 16℃metal bath using T4DNA ligase (NEB), and DH-5a competent cells were transformed the next day, and resistance screening was performed by coating ampicillin solid medium containing 100. Mu.g/mL. Single colonies on the plates were picked and inoculated into LB liquid medium containing 100. Mu.g/mL ampicillin to grow to the plateau phase, and after plasmid extraction, bamHI and SalI single enzyme digestion and two restriction enzymes double enzyme digestion were performed. Preparing 1% agarose gel, carrying out electrophoresis for 45min at 110V, then dyeing by using ethidium bromide, and imaging under an ultraviolet imager, wherein the result is shown in FIG. 13, and the BamHI and SalI single cleavage products of the recombinant plasmid pBR-YaiU-Hp-VacA-TBEA-AD11 are 7118bp; the double enzyme digestion product bacteria of the two vectors comprise a 4085bp linear vector and a 3033bp yaiU-Hp-VacA-TBEA-AD11 linear DNA fragment, which are consistent with the expected size.
DH-5 alpha engineering bacteria carrying recombinant plasmid pBR-YaiU-Hp-VacA-TBEA-AD11 are grown in ampicillin LB liquid medium containing 100 mu g/mL to a post-log stage, centrifuged at 4000rpm for 5min, the supernatant is discarded, resuspended in an equal volume of sterile physiological saline, and washed by continuous centrifugation for 2 times to prepare bacterial suspension (final concentration 1X 10) 10 CFU/mL). Recombinant DH-5 alpha engineering bacteria bacterial suspension carrying the recombinant plasmid is respectively subjected to agglutination test with Hp-VacA negative serum (10 parts of SPF mouse serum and healthy human volunteer serum respectively) and Hp positive serum (10 parts of artificially infected mouse serum and 10 parts of volunteer serum of Hp infection diagnosis patient), and bacterial suspension containing pBR-YaiU DH-5 alpha engineering bacteria is used as negative control. The results are shown in Table 8, with bacterial suspensions of all strains not reacting with negative serum; the bacterial suspension of recombinant DH-5 alpha engineering bacteria carrying recombinant plasmid pBR-YaiU-Hp-VacA-TBEA-AD11 and positive serum have obvious agglutination phenomenon, large agglutination particles and clear background; DH-5 alpha engineering bacteria containing pBR-YaiU plasmid onlyNeither the bacterial suspension nor the positive serum is agglutinated, no agglutinated particles exist, and the background is turbid. The results indicate that B cell epitope target antigen (TBEA) from Hp-VacA is capable of achieving cell surface expression through the V-type secretion system YaiU, and is capable of specifically detecting antibodies against Hp.
In the antibody detection system, DH-5alpha+pBR-YaiU bacterial suspension is used as a control system, and the antibody detection system only increases TBEA, specifically recognizes and binds specific antibodies and eliminates false positive reaction, thereby ensuring accurate diagnosis of individuals; DH-5α+pBR-YaiU-Hp-VacA-TBEA-AD11 bacterial suspension is used as a specific antibody detection system guided by Hp target antigen, and specifically recognizes the antibody aiming at the Hp-VacA target antigen.
TABLE 8 functional verification of the expression of YaiU-Hp-VacA-TBEA on the DH-5. Alpha. Surface of vector bacteria
Note that: "-" represents negative for agglutination; "+" indicates positive agglutination
EXAMPLE 6 specificity and sensitivity test of Hp-VacA agglutination antibody detection System
Based on the functional verification of the expression YaiU-Hp-VacA-TBEA on the surface of carrier bacteria DH-5 alpha, the specificity and sensitivity of the Hp agglutination antibody detection system are further tested, and the specific implementation procedure is as follows:
according to the same manner as in example 5, a control system DH-5α+pBR-YaiU bacterial suspension and a Hp agglutination antibody detection system DH-5α+pBR-YaiU-Hp-VacA-TBEA-AD11 bacterial suspension were prepared. The three bacterial suspensions are respectively subjected to agglutination tests with serum from different background sources to verify the specificity of the agglutination antibody detection system, and the serum involved in detection comprises: 100 healthy human volunteers (uninfected helicobacter pylori) serum (provided by the university of in the Yangzhou department of Subei medical science Zhu Guojiang professor group), 8 healthy SPF mouse serum (provided by the university of in the Yangzhou department of comparative medical science Zhu Guojiang professor group), 40 human volunteer serum (provided by the university of in the Yangzhou department of Subei medical science Zhu Guojiang professor group), 10 human infected helicobacter pylori mouse serum (provided by the university of in the Yangzhou department of comparative medical science Zhu Guojiang professor group), 1 mouse liver-positive serum (provided by the university of in the Yangzhou department of comparative medical science Zhang Quan professor group), 8 human campylobacter jejuni positive serum (provided by the university of in the North medical science Xu Fuzhou professor group), 10O 2 E.coli positive serum (provided by the university of comparative medical science Zhu Guojiang professor group in the Yangzhou department of China), 10O 78 E.coli positive serum (provided by the university of comparative medical science Zhu Guojiang professor group in the Yangzhou department of China), 10O 157 E.coli positive serum (provided by the university of high-university of comparative medical science Zhu Guojiang), 10 E.coli positive serum (provided by the professor group in the Yangzhou department of China department of comparative medical science Zhu Guojiang) and 10 E.g. positive serum (provided by the professor group in the Yangzhou department of the university of China department of comparative medical science Zhu Guojiang). As shown in Table 9, the serum of volunteer from 40 patients diagnosed with helicobacter pylori infection and the serum of mice artificially infected with helicobacter pylori did not agglutinate with the control system, but did agglutinate with the Hp-VacA antibody detection system; meanwhile, the system does not have agglutination reaction with healthy individual (helicobacter pylori uninfected) serum, healthy SPF mouse serum, liver screw positive serum, jejunum campylobacter infection positive serum, O2 colibacillus positive serum, O78 colibacillus positive serum, O157 colibacillus positive serum, duck salmonella positive serum and salmonella typhimurium positive serum, and the specificity is 100%. The agglutination pattern of the serum samples is shown in FIG. 15.
TABLE 9 specificity verification of Hp-VacA target antigen directed agglutination antibody detection systems
Note that: "-" represents negative for agglutination; "+" indicates positive agglutination
To clarify the test sensitivity of the present invention, 10C 57BL/6 mice were infected with the helicobacter pylori standard strain NTCT11639 (day 1), and the serum of the above mice was collected by tail vein blood sampling on the day before infection (day 0) as a negative control. All mice were collected whole blood and serum was prepared daily from day 1 to day 15 post infection using tail vein blood collection, and then quantitatively tested using the Hp-VacA target antigen directed agglutination antibody detection system. The test mode is as follows: subjecting the 160 parts of serum to 2 n Dilution of the double ratio: adding 10 μl of sterile physiological saline into each well of 96-well plate, then sucking 10 μl of serum into the first well of each column, mixing with sterile physiological saline thoroughly, adding 10 μl of diluted serum into the next well, and continuously diluting to 2 in circulation 6 Multiple times. The serum of each dilution was subjected to agglutination tests with DH-5α+pBR-YaiU and DH-5α+pBR-YaiU-Hp-VacA-TBEA-AD11 bacterial suspensions, respectively, with DH-5α+pBR-YaiU as negative control and the last dilution at which agglutinating particles appeared as the serum antibody titer. The positive and positive rate results of the agglutination test are shown in table 10, with agglutination antibodies being detected at earliest day 5 in infected mice, with sensitivity significantly higher than that of conventional serological detection techniques, and with increasing duration of infection, the positive rate of the agglutination test increases gradually; the quantitative test results are shown in FIG. 16, and at day 14 post immunization, it was found that the titer of the infection agglutination antibody reached 1:16.
In conclusion, the Hp-VacA target antigen agglutination antibody test method has good specificity and sensibility. Compared with the results reported by the current immunological detection methods (colloidal gold, immunoluminescence, ELISA and the like) aiming at Hp-VacA complete protein antigen, the specificity and sensitivity of the technology are remarkably improved, and the titer of the specific agglutination antibody can be quantitatively detected.
TABLE 10 sensitivity verification of Hp-VacA target antigen directed agglutination antibody detection systems
Claims (10)
1. A B cell epitope target antigen carrying helicobacter pylori virulence factor VacA, characterized in that the amino acid sequence of the target antigen is ANVEARYYYGD.
2. A nucleic acid or gene encoding the target antigen of claim 1, wherein the DNA sequence of the nucleic acid or gene is GCTAATGTGGAAGCGCGCTATTATTATGGAGAC.
3. An expression cassette, a recombinant expression vector, a recombinant strain, comprising the nucleic acid or gene of claim 2.
4. An agglutination antibody detection system, characterized in that it comprises the expression cassette, recombinant expression vector or recombinant strain of claim 3.
5. The recombinant expression vector according to claim 3, wherein the recombinant expression vector is constructed by inserting the nucleic acid or gene of the target antigen according to claim 2 into the gene sequence of the YaiU-type V-type secretion system of salmonella gallinarum.
6. A recombinant strain according to claim 3, wherein the recombinant strain comprises a recombinant expression vector introduced into a vector bacterium.
7. The recombinant expression vector according to claim 3 or 5, the agglutination antibody detection system according to claim 4, or the recombinant strain construction method according to claim 6, characterized by comprising the steps of:
(1) Obtaining a DNA sequence encoded by a B cell epitope target antigen carrying helicobacter pylori virulence factor VacA; the DNA sequence is GCTAATGTGGAAGCGCGCTATTATTATGGAGAC;
(2) Inserting the DNA sequence obtained in the step (1) into a YaiU type V-type secretion system gene sequence of salmonella gallinarum to construct a recombinant expression vector; or/and;
(3) And (3) introducing the recombinant expression vector obtained in the step (2) into a vector bacterium in an electrotransformation mode to obtain the recombinant strain.
8. Use of the target antigen of claim 1, the nucleic acid or gene encoding the target antigen of claim 2, the expression cassette, recombinant vector, recombinant strain or agglutination antibody detection system of claim 3 for the preparation of a reagent or kit for detecting helicobacter pylori agglutination antibodies.
9. An agglutination antibody which binds to a B cell epitope target antigen of helicobacter pylori virulence factor VacA, characterized in that the agglutination antibody specifically binds to the B cell epitope target antigen of claim 1.
10. A reagent or kit for detecting an agglutination antibody against helicobacter pylori, characterized in that the reagent or kit comprises the helicobacter pylori virulence factor B cell epitope target antigen according to claim 1, the expression cassette according to claim 3, a recombinant vector, a recombinant strain or the agglutination antibody detection system according to claim 4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211599991.0A CN116120408B (en) | 2022-12-09 | 2022-12-09 | B cell epitope target antigen carrying helicobacter pylori virulence factor, expression vector and application thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211599991.0A CN116120408B (en) | 2022-12-09 | 2022-12-09 | B cell epitope target antigen carrying helicobacter pylori virulence factor, expression vector and application thereof |
| CN202211587776.9A CN116375823B (en) | 2022-12-09 | 2022-12-09 | B cell epitope target antigen carrying helicobacter pylori virulence factor, expression vector and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211587776.9A Division CN116375823B (en) | 2022-12-09 | 2022-12-09 | B cell epitope target antigen carrying helicobacter pylori virulence factor, expression vector and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116120408A true CN116120408A (en) | 2023-05-16 |
| CN116120408B CN116120408B (en) | 2023-10-20 |
Family
ID=86316301
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211587776.9A Active CN116375823B (en) | 2022-12-09 | 2022-12-09 | B cell epitope target antigen carrying helicobacter pylori virulence factor, expression vector and application thereof |
| CN202211599991.0A Active CN116120408B (en) | 2022-12-09 | 2022-12-09 | B cell epitope target antigen carrying helicobacter pylori virulence factor, expression vector and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211587776.9A Active CN116375823B (en) | 2022-12-09 | 2022-12-09 | B cell epitope target antigen carrying helicobacter pylori virulence factor, expression vector and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN116375823B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998027432A1 (en) * | 1996-12-19 | 1998-06-25 | Chiron Corporation | Helicobacter pylori diagnostics |
| AU2003201353A1 (en) * | 1997-11-06 | 2003-06-12 | Delfts Diagnostic Laboratory B.V. | Detection and typing of the iceA gene of Helicobacter pylori |
| CN101033468A (en) * | 2007-02-05 | 2007-09-12 | 中国人民解放军第三军医大学 | Helicobacter pylori urease B subunit B cell antigen epitope polypeptide, identification method and application |
| CN101096656A (en) * | 2007-05-24 | 2008-01-02 | 重庆医科大学 | Helicobacter pylori recombinant VacA monoclonal antibody and uses thereof |
| CN108956989A (en) * | 2018-09-27 | 2018-12-07 | 重庆新赛亚生物科技有限公司 | A kind of classification of helicobacter pylori detection detection reagent card and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010019834A1 (en) * | 1997-03-31 | 2001-09-06 | Byung-O Kim | Recombinant microorganisms expressing antigenic proteins of helicobacter pylori |
| CN101082623B (en) * | 2007-07-12 | 2011-11-16 | 福建医科大学 | Preparation of detecting reagent of helicobacter pylori high virulence |
| CN101863964B (en) * | 2010-05-21 | 2013-06-05 | 中国人民解放军军事医学科学院生物工程研究所 | Helicobacter pylori urease B antigen epitope polypeptide and application thereof |
| CN102721815A (en) * | 2012-04-18 | 2012-10-10 | 天津天佛罗生物技术有限公司 | Detection kit for helicobacter pylori virulence protein antibody and detection method by using the same |
| WO2015151128A1 (en) * | 2014-04-04 | 2015-10-08 | Over S.R.L. | Method for rapid detection of infection from caga positive helicobacter pylori and diagnostic kit therefor |
-
2022
- 2022-12-09 CN CN202211587776.9A patent/CN116375823B/en active Active
- 2022-12-09 CN CN202211599991.0A patent/CN116120408B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998027432A1 (en) * | 1996-12-19 | 1998-06-25 | Chiron Corporation | Helicobacter pylori diagnostics |
| AU2003201353A1 (en) * | 1997-11-06 | 2003-06-12 | Delfts Diagnostic Laboratory B.V. | Detection and typing of the iceA gene of Helicobacter pylori |
| CN101033468A (en) * | 2007-02-05 | 2007-09-12 | 中国人民解放军第三军医大学 | Helicobacter pylori urease B subunit B cell antigen epitope polypeptide, identification method and application |
| CN101096656A (en) * | 2007-05-24 | 2008-01-02 | 重庆医科大学 | Helicobacter pylori recombinant VacA monoclonal antibody and uses thereof |
| CN108956989A (en) * | 2018-09-27 | 2018-12-07 | 重庆新赛亚生物科技有限公司 | A kind of classification of helicobacter pylori detection detection reagent card and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 李妍: "幽门螺杆菌主要保护性抗原的基因克隆、表达、单克隆抗体制 备及其B细胞表位的鉴定", 中国博士学位论文全文数据库医药卫生科技辑, no. 2, pages 059 - 48 * |
| 李雅倩: "幽门螺杆菌检测技术研究进展及展望", 微生物学报, vol. 62, no. 5, pages 1645 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116375823B (en) | 2024-02-23 |
| CN116120408B (en) | 2023-10-20 |
| CN116375823A (en) | 2023-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102573896B (en) | Composition and the method for Much's bacillus immunodominance antigen | |
| CN105461805B (en) | Monoclonal Antibodies against Porcine Epidemic Diarrhea Virus and its application | |
| CN111537712B (en) | Inert carrier indirect agglutination test detection system and application thereof | |
| EP3146338B1 (en) | Method for rapid detection of infection from caga positive helicobacter pylori and diagnostic kit therefor | |
| CN110327460A (en) | Streptococcus suis-Haemophilus parasuis bigeminy subunit vaccine and preparation method | |
| CN107304231B (en) | Mycobacterium tuberculosis fusion protein and application thereof | |
| Fatehi et al. | Oral vaccination with novel Lactococcus lactis mucosal live vector-secreting Brucella lumazine synthase (BLS) protein induces humoral and cellular immune protection against Brucella abortus | |
| CN110483625A (en) | A kind of Mycoplasma bovis imagination albumen MbovP732 and its application | |
| Sweger et al. | Conservation of the 17-kilodalton antigen gene within the genus Bartonella | |
| CN116445448B (en) | Acinetobacter baumannii PLPFP recombinant protein, preparation method and application | |
| CN116120408B (en) | B cell epitope target antigen carrying helicobacter pylori virulence factor, expression vector and application thereof | |
| CN116284349B (en) | Monkey pox antibody detection kit | |
| US10022458B2 (en) | Animal model protocol, diagnostic, therapeutic and vaccine against digital dermatitis | |
| CN111621506A (en) | Mycoplasma bovis secretory protein Mbovp0145 and application thereof | |
| CN105693831A (en) | Livestock S2 vaccine immunity and Brucella melitensis/abortus infection IELISA (enzyme linked immunosorbent assay) detection reagent | |
| CN113181349B (en) | M cell-targeted multi-epitope oral vaccine and application thereof in hydatid vaccine | |
| CN115716867B (en) | V-type secretion system MisL exhibiting expression novel coronavirus receptor binding domain B cell epitope antigen and application | |
| CN111704661B (en) | Application of schistosoma japonicum schistosomulum high-expression gene or coding protein thereof | |
| CN116715737B (en) | Novel target antigen of coronavirus receptor binding domain B cell epitope and expression and application thereof in Peg bacterium Mao Zhan | |
| CN113754782A (en) | Helicobacter pylori egg yolk antibody and preparation method and application thereof | |
| Gu et al. | Sef fimbria operon construction, expression, and function for direct rapid detection of Salmonella Enteritidis | |
| CN106706904B (en) | White diarrhea antibody latex agglutination bears selective mechanisms kit and preparation method and application | |
| CN116425865B (en) | Antibodies and their use in monkey poxvirus detection | |
| CN116462743B (en) | Acinetobacter baumannii translation elongation factor recombinant protein, preparation method and application | |
| CN112481287B (en) | Recombinant bacterium for expressing SEF14 functional pilus and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230921 Address after: 225009 No. 88, South University Road, Jiangsu, Yangzhou Applicant after: YANGZHOU University Applicant after: WUXI XISHAN PEOPLE'S Hospital Address before: 225009 No. 88, South University Road, Jiangsu, Yangzhou Applicant before: YANGZHOU University |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |